ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT
pioglitazone
The following articles have the tag pioglitazone
Caution advised after pioglitazone linked to bladder cancer
THE TGA has issued a safety advisory for pioglitazone (Actos) following research linking long-term use to an increased risk of bladder cancer. A US study found patients with type 2 diabetes taking the medication for more than 24 months had 1.4 times the cancer risk of patients not taking it. A preliminary assessment of data from a French trial also showed an increased risk of bladder cancer in patients taking the drug for more than 12 months, the TGA said. “The TGA is advising health professionals and consumers that use of the diabetes medicine, pioglitazone, for ...
Glitazone cuts conversion to type 2 at a cost
PIOGLITAZONE can reduce conversion to type 2 diabetes but at a cost of weight gain and oedema, a trial has shown. US researchers studied the effects of 30 mg pioglitazone per day compared with placebo in 600 patients with impaired glucose tolerance and baseline mean BMI of 34.5. Pioglitazone reduced the risk of converting from impaired glucose tolerance to type 2 diabetes by 72% over 2.4 years (48% pioglitazone vs 28% placebo), the manufacturer-supported study found. Treatment of 18 participants for a year prevented one case of diabetes. However, weight gain in the pioglitazone group was ...
Early data linking pioglitazone with cancer under investigation
US regulators are investigating a possible link between pioglitazone and bladder cancer, based on early data supplied by the drug’s manufacturer. No link has been proven yet, and the FDA says patients should continue taking the drug. An observational study has flagged a possible link in patients with the longest exposure to the drug and highest cumulative doses, the US Food and Drug Administration (FDA) said. Eli Lily, distributors of pioglitazone in Australia, were unable to comment on the FDA’s announcement at time of going to press. The announcement comes at a troubled time for ...
Fatty liver treatments promising but evidence needed
Australia & New Zealand Medical & Surgical Gastrointestinal Week 2009, Sydney A RANGE of promising treatments are currently available for patients with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), an Australian expert says. However, Dr Amany Zekry, a gastroenterologist at St George Hospital in NSW, said there was limited evidence upon which to formulate treatment advice due to a lack of suitable studies. Speaking at the recent conference, she said available data was hampered by studies lacking randomisation or having small samples. “There is no single medication that can be recommended ...
New debate over glitazone safety
TREATMENT with the thiazolidinedione, rosiglitazone, results in more deaths from any cause than does treatment with pioglitazone, a study of elderly patients with diabetes has confirmed. However, an Australian expert said the latest findings did not provide further clarity on the safety of each agent. A cohort study of more than 28,000 US patients older than 65 years, with type 2 diabetes, found those using rosiglitazone had a 15% greater rate of all-cause mortality and a 13% greater incidence of hospitalisation than those using pioglitazone. The rosiglitazone group also had a 13% higher risk of congestive ...